{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T21:46:21Z","timestamp":1778881581983,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA006927"],"award-info":[{"award-number":["P30 CA006927"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.clml.2016.11.005","type":"journal-article","created":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T01:57:47Z","timestamp":1480471067000},"page":"83-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Low Level of Blood CD4+ T Cells Is an Independent Predictor of Inferior Progression-free Survival in Diffuse Large B-cell Lymphoma"],"prefix":"10.1016","volume":"17","author":[{"given":"Julia","family":"Judd","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Essel","family":"Dulaimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael M.","family":"Millenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Borghaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tahseen","family":"Al-Saleem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2016.11.005_bib1","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1182\/asheducation-2011.1.498","article-title":"Relapsed\/refractory diffuse large B-cell lymphoma","volume":"2011","author":"Friedberg","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2016.11.005_bib2","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1056\/NEJM199402243300815","article-title":"A\u00a0predictive model for non-Hodgkin's lymphoma","volume":"330","author":"Atkins","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2016.11.005_bib3","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.11.005_bib4","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","article-title":"An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.11.005_bib5","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2016.11.005_bib6","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1182\/blood-2006-09-047068","article-title":"Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy","volume":"109","author":"Nyman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.11.005_bib7","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1200\/JCO.2001.19.3.720","article-title":"CD4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome","volume":"19","author":"Ansell","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2016.11.005_bib8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/ajh.23398","article-title":"CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy","volume":"88","author":"Keane","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2016.11.005_bib9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3324\/haematol.2013.088161","article-title":"Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era","volume":"99","author":"Tadmor","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2016.11.005_bib10","doi-asserted-by":"crossref","first-page":"e102594","DOI":"10.1371\/journal.pone.0102594","article-title":"A\u00a0new prognostic score for elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: the prognostic role of blood monocyte and lymphocyte counts is absent","volume":"9","author":"Prochazka","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2016.11.005_bib11","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/ejh.12221","article-title":"Peripheral blood absolute lymphocyte\/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era","volume":"92","author":"Watanabe","year":"2014","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2016.11.005_bib12","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s00277-013-1916-9","article-title":"Peripheral blood lymphocyte\/monocyte ratio predicts outcome for patients with diffuse large B cell lymphoma after standard first-line regimens","volume":"93","author":"Li","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2016.11.005_bib13","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1093\/annonc\/mdm110","article-title":"Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma","volume":"18","author":"Plonquet","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2016.11.005_bib14","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2141.2008.07028.x","article-title":"Absolute lymphocyte count is a prognostic factor in diffuse large B-cell lymphoma","volume":"141","author":"Cox","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2016.11.005_bib15","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1046\/j.1365-2141.2001.02649.x","article-title":"Prognostic significance of tumour-infiltrating T lymphocytes and T-cell subsets in de novo diffuse large B-cell lymphoma: a multiparameter flow cytometry study","volume":"112","author":"Xu","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2016.11.005_bib16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1310\/hct0803-132","article-title":"Improved survival in HIV-associated diffuse large B-cell lymphoma with the addition of rituximab to chemotherapy in patients receiving highly active antiretroviral therapy","volume":"8","author":"Ezzat","year":"2007","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.clml.2016.11.005_bib17","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1093\/annonc\/mdp531","article-title":"Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story","volume":"21","author":"Bari","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2016.11.005_bib18","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.leukres.2013.07.038","article-title":"Low NK cell counts in peripheral blood are associated with inferior overall survival in patients with follicular lymphoma","volume":"37","author":"Shafer","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2016.11.005_bib19","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.3109\/10428194.2014.893313","article-title":"Peripheral blood absolute lymphocyte\/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma","volume":"55","author":"Porrata","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2016.11.005_bib20","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.3109\/10428194.2015.1014367","article-title":"Prognostic role of peripheral blood lymphocyte\/monocyte ratio at diagnosis in diffuse large B-cell lymphoma: a meta-analysis","volume":"56","author":"Lin","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2016.11.005_bib21","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1182\/blood-2004-02-0762","article-title":"Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome","volume":"104","author":"Novak","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.11.005_bib22","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1080\/10428190701549562","article-title":"Elevated serum BLyS levels in patients with non-Hodgkin lymphoma","volume":"48","author":"Oki","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2016.11.005_bib23","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1189\/jlb.0905495","article-title":"Monocyte\/macrophage infiltration in tumors: modulators of angiogenesis","volume":"80","author":"Dirkx","year":"2006","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.clml.2016.11.005_bib24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/PPO.0000000000000164","article-title":"Checkpoint inhibition: programmed cell death 1 and programmed cell death 1 ligand inhibitors in Hodgkin lymphoma","volume":"22","author":"Villasboas","year":"2016","journal-title":"Cancer J"},{"key":"10.1016\/j.clml.2016.11.005_bib25","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1517\/13543784.2015.1038342","article-title":"Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma","volume":"24","author":"Merli","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clml.2016.11.005_bib26","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1146\/annurev-med-051914-021702","article-title":"CAR-T cell therapy for lymphoma","volume":"67","author":"Ramos","year":"2016","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.clml.2016.11.005_bib27","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","article-title":"Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma","volume":"126","author":"Kiyasu","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2016.11.005_bib28","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/ejh.12144","article-title":"Association of circulating regulatory T cell number with the incidence and prognosis of diffuse large B-cell lymphoma","volume":"91","author":"Glowala-Kosinska","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2016.11.005_bib29","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.3109\/10428194.2013.879713","article-title":"An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone","volume":"55","author":"Nam","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2016.11.005_bib30","doi-asserted-by":"crossref","first-page":"980","DOI":"10.2741\/s114","article-title":"CD4 (+)CD25 (+)Foxp3 (+) regulatory T cells and hematologic malignancies","volume":"2","author":"Kelley","year":"2010","journal-title":"Front Biosci"},{"key":"10.1016\/j.clml.2016.11.005_bib31","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3324\/haematol.2010.028241","article-title":"CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma","volume":"96","author":"Ait-Tahar","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2016.11.005_bib32","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/tan.12329","article-title":"Tumor antigen-specific CD4+ T cells in cancer immunity: from antigen identification to tumor prognosis and development of therapeutic strategies","volume":"83","author":"Protti","year":"2014","journal-title":"Tissue Antigens"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016308680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016308680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:28:17Z","timestamp":1761870497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265016308680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["S2152265016308680"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2016.11.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low Level of Blood CD4+ T Cells Is an Independent Predictor of Inferior Progression-free Survival in Diffuse Large B-cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2016.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}